Abstract
Patients with ALK -rearranged non–small-cell lung cancer (NSCLC) benefit from anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib and ceritinib, although almost all experience progression, and many develop central nervous system (CNS) metastases as the first site of progression. Now, investigators have conducted an industry-supported, global, single-arm, phase II study to assess the efficacy and safety of the newly approved, oral tyrosine kinase ALK inhibitor alectinib (600 mg twice daily) in 138 patients with crizotinib-refractory ALK -positive disease. Of these, 61% had …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
